

Roger N Gunn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7746487/publications.pdf>

Version: 2024-02-01

247
papers

19,268
citations

15504

65
h-index

12946

131
g-index

272
all docs

272
docs citations

272
times ranked

15156
citing authors

#	ARTICLE	IF	CITATIONS
1	Adenosine A2A receptor in schizophrenia: an in vivo brain PET imaging study. <i>Psychopharmacology</i> , 2022, 239, 3439-3445.	3.1	8
2	Endogenous dopamine release in the human brain as a pharmacodynamic biomarker: evaluation of the new GPR139 agonist TAK-041 with [¹¹ C]PHNO PET. <i>Neuropsychopharmacology</i> , 2022, 47, 1405-1412.	5.4	9
3	Kinetic modelling of dissolution dynamic nuclear polarisation ¹³ C magnetic resonance spectroscopy data for analysis of pyruvate delivery and fate in tumours. <i>NMR in Biomedicine</i> , 2022, 35, e4650.	2.8	1
4	Relationship between astrocyte reactivity, using novel ¹¹ C-BU99008 PET, and glucose metabolism, grey matter volume and amyloid load in cognitively impaired individuals. <i>Molecular Psychiatry</i> , 2022, 27, 2019-2029.	7.9	19
5	Test-retest variability and reference region-based quantification of ¹⁸ F-BCPP-EF for imaging mitochondrial complex I in the human brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 771-779.	4.3	15
6	PET image reconstruction using physical and mathematical modelling for time of flight PET-MR scanners in the STIR library. <i>Methods</i> , 2021, 185, 110-119.	3.8	16
7	Tau ^{IQ} : A Canonical Image Based Algorithm to Quantify Tau PET Scans. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1292-1300.	5.0	13
8	A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [¹⁸ F]flutemetamol amyloid PET images. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2183-2199.	6.4	16
9	Reproducibility of findings in modern PET neuroimaging: insight from the NRM2018 grand challenge. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 2778-2796.	4.3	10
10	The relationship between synaptic density marker SV2A, glutamate and N-acetyl aspartate levels in healthy volunteers and schizophrenia: a multimodal PET and magnetic resonance spectroscopy brain imaging study. <i>Translational Psychiatry</i> , 2021, 11, 393.	4.8	27
11	Astrocyte reactivity with late-onset cognitive impairment assessed in vivo using ¹¹ C-BU99008 PET and its relationship with amyloid load. <i>Molecular Psychiatry</i> , 2021, 26, 5848-5855.	7.9	43
12	Acute acetate administration increases endogenous opioid levels in the human brain: A [¹¹ C]carfentanil molecular imaging study. <i>Journal of Psychopharmacology</i> , 2021, 35, 606-610.	4.0	3
13	The role of phosphodiesterase 4 in excessive daytime sleepiness in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2020, 77, 163-169.	2.2	11
14	Blunted endogenous opioid release following an oral dexamphetamine challenge in abstinent alcohol-dependent individuals. <i>Molecular Psychiatry</i> , 2020, 25, 1749-1758.	7.9	23
15	Characterization of 3 PET Tracers for Quantification of Mitochondrial and Synaptic Function in Healthy Human Brain: ¹⁸ F-BCPP-EF, ¹¹ C-SA-4503, and ¹¹ C-UCB-J. <i>Journal of Nuclear Medicine</i> , 2020, 61, 96-103.	5.0	53
16	Preclinical evaluation of [¹⁸ F]FB-A20FMDV2 as a selective marker for measuring $\alpha_5\beta_1$ integrin occupancy using positron emission tomography in rodent lung. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 958-966.	6.4	5
17	Serotonin release measured in the human brain: a PET study with [¹¹ C]CIMBI-36 and d-amphetamine challenge. <i>Neuropsychopharmacology</i> , 2020, 45, 804-810.	5.4	34
18	Clinical quantification of the integrin $\alpha_5\beta_1$ by [¹⁸ F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 967-979.	6.4	43

#	ARTICLE	IF	CITATIONS
19	Longitudinal (¹⁸ F)AV-1451 PET imaging in a patient with frontotemporal dementia due to a Q351R MAPT mutation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 106-108.	1.9	8
20	PET Parametric Imaging: Past, Present, and Future. <i>IEEE Transactions on Radiation and Plasma Medical Sciences</i> , 2020, 4, 663-675.	3.7	54
21	Consensus Recommendations on the Use of ¹⁸ F-FDG PET/CT in Lung Disease. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1701-1707.	5.0	8
22	Tau pathology in early Alzheimer's disease is linked to selective disruptions in neurophysiological network dynamics. <i>Neurobiology of Aging</i> , 2020, 92, 141-152.	3.1	34
23	Nonlinear biomarker interactions in conversion from mild cognitive impairment to Alzheimer's disease. <i>Human Brain Mapping</i> , 2020, 41, 4406-4418.	3.6	23
24	Guidelines for the content and format of PET brain data in publications and archives: A consensus paper. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 1576-1585.	4.3	47
25	Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats. <i>Nature Communications</i> , 2020, 11, 246.	12.8	148
26	DREADD Activation of Pedunculopontine Cholinergic Neurons Reverses Motor Deficits and Restores Striatal Dopamine Signaling in Parkinsonian Rats. <i>Neurotherapeutics</i> , 2020, 17, 1120-1141.	4.4	18
27	Mitochondrial Complex 1, Sigma 1, and Synaptic Vesicle ^{2A} in Early Drug-Naive Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 1416-1427.	3.9	48
28	Building a database for brain 18 kDa translocator protein imaged using [¹¹ C]PBR28 in healthy subjects. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019, 39, 1138-1147.	4.3	16
29	Dopamine D2/D3 receptor abnormalities after traumatic brain injury and their relationship to post-traumatic depression. <i>NeuroImage: Clinical</i> , 2019, 24, 101950.	2.7	15
30	In vivo detection of cerebral tau pathology in long-term survivors of traumatic brain injury. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	56
31	Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson's disease: an in vivo ¹¹ C-BU99008 PET study. <i>Brain</i> , 2019, 142, 3116-3128.	7.6	73
32	Accuracy and reliability of [¹¹ C]PBR28 specific binding estimated without the use of a reference region. <i>NeuroImage</i> , 2019, 188, 102-110.	4.2	18
33	Serotonergic pathology and disease burden in the premotor and motor phase of A53T α -synuclein parkinsonism: a cross-sectional study. <i>Lancet Neurology</i> , The, 2019, 18, 748-759.	10.2	70
34	Imaging of Chemotherapy-Induced Acute Cardiotoxicity with ¹⁸ F-Labeled Lipophilic Cations. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1750-1756.	5.0	26
35	Comparison of phosphodiesterase 10A and dopamine transporter levels as markers of disease burden in early Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 1505-1515.	3.9	15
36	Relationship between neuromelanin and dopamine terminals within the Parkinson's nigrostriatal system. <i>Brain</i> , 2019, 142, 2023-2036.	7.6	48

#	ARTICLE	IF	CITATIONS
37	Deep and Frequent Phenotyping study protocol: an observational study in prodromal Alzheimer's disease. <i>BMJ Open</i> , 2019, 9, e024498.	1.9	18
38	Confirmation of Specific Binding of the 18-kDa Translocator Protein (TSPO) Radioligand [18F]GE-180: a Blocking Study Using XBD173 in Multiple Sclerosis Normal Appearing White and Grey Matter. <i>Molecular Imaging and Biology</i> , 2019, 21, 935-944.	2.6	32
39	Amyloid Load: A More Sensitive Biomarker for Amyloid Imaging. <i>Journal of Nuclear Medicine</i> , 2019, 60, 536-540.	5.0	40
40	Abstract 1144: Imaging radiotherapy induced pulmonary fibrogenic changes with integrin-PET. , 2019, , .		1
41	Gait in Mild Alzheimer's Disease: Feasibility of Multi-Center Measurement in the Clinic and Home with Body-Worn Sensors: A Pilot Study. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 331-341.	2.6	42
42	Translocator Protein as an Imaging Marker of Macrophage and Stromal Activation in Rheumatoid Arthritis Pannus. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1125-1132.	5.0	46
43	Minocycline reduces chronic microglial activation after brain trauma but increases neurodegeneration. <i>Brain</i> , 2018, 141, 459-471.	7.6	143
44	Imaging A β 2 and tau in early stage Alzheimer's disease with [18F]AV45 and [18F]AV1451. <i>EJNMMI Research</i> , 2018, 8, 19.	2.5	14
45	Evaluation of ¹¹ C-BU99008, a PET Ligand for the Imidazoline ₂ Binding Site in Human Brain. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1597-1602.	5.0	61
46	¹¹ C-DPA-713 has much greater specific binding to translocator protein 18 kDa (TSPO) in human brain than ¹¹ C-(R)-PK11195. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2018, 38, 393-403.	4.3	51
47	Thermal Imaging Is a Noninvasive Alternative to PET/CT for Measurement of Brown Adipose Tissue Activity in Humans. <i>Journal of Nuclear Medicine</i> , 2018, 59, 516-522.	5.0	51
48	Spatiotemporal Distribution of β -Amyloid in Alzheimer Disease Is the Result of Heterogeneous Regional Carrying Capacities. <i>Journal of Nuclear Medicine</i> , 2018, 59, 822-827.	5.0	44
49	Quantification of human brain PDE4 occupancy by GSK356278: A [11C](R)-rolipram PET study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2018, 38, 2033-2040.	4.3	6
50	First evaluation of PET-based human biodistribution and radiation dosimetry of ¹¹ C-BU99008, a tracer for imaging the imidazoline ₂ binding site. <i>EJNMMI Research</i> , 2018, 8, 71.	2.5	12
51	PDE10A and ADCY5 mutations linked to molecular and microstructural basal ganglia pathology. <i>Movement Disorders</i> , 2018, 33, 1961-1965.	3.9	38
52	Disease-related patterns of in vivo pathology in Corticobasal syndrome. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2413-2425.	6.4	26
53	Implementation of Image Reconstruction for GE SIGNA PET/MR PET Data in the STIR Library. , 2018, , .		2
54	PET-MR Attenuation Correction in Dynamic Brain PET Using [¹¹ C]Cimbi-36: A Direct Comparison With PET-CT. <i>IEEE Transactions on Radiation and Plasma Medical Sciences</i> , 2018, 2, 483-489.	3.7	11

#	ARTICLE	IF	CITATIONS
55	Modelling the progression of Alzheimer's disease in MRI using generative adversarial networks. , 2018, , .		23
56	Quantification of Lung PET Images: Challenges and Opportunities. Journal of Nuclear Medicine, 2017, 58, 201-207.	5.0	55
57	Decreased hippocampal translocator protein (18â€‰kDa) expression in alcohol dependence: a [¹¹ C]PBR28 PET study. Translational Psychiatry, 2017, 7, e996-e996.	4.8	56
58	Translocator positron-emission tomography and magnetic resonance spectroscopic imaging of brain glial cell activation in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 1469-1478.	3.0	23
59	¹¹ C-PBR28 and ¹⁸ F-PBR111 Detect White Matter Inflammatory Heterogeneity in Multiple Sclerosis. Journal of Nuclear Medicine, 2017, 58, 1477-1482.	5.0	57
60	Evidence for GABAâ€‰A receptor dysregulation in gambling disorder: correlation with impulsivity. Addiction Biology, 2017, 22, 1601-1609.	2.6	24
61	Neuroinflammation and its relationship to changes in brain volume and white matter lesions in multiple sclerosis. Brain, 2017, 140, 2927-2938.	7.6	75
62	Brain lesion segmentation through image synthesis and outlier detection. NeuroImage: Clinical, 2017, 16, 643-658.	2.7	38
63	Loss of phosphodiesterase 4 in Parkinson disease. Neurology, 2017, 89, 586-593.	1.1	30
64	Quantitative analysis of dynamic ¹⁸ F-FDG PET/CT for measurement of lung inflammation. EJNMMI Research, 2017, 7, 47.	2.5	23
65	Imaging in Central Nervous System Drug Discovery. Seminars in Nuclear Medicine, 2017, 47, 89-98.	4.6	38
66	Quantification of [¹¹ C]Ro15-4513 GABAA \pm 5 specific binding and regional selectivity in humans. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 2137-2148.	4.3	26
67	[P4â€‰529]: AMYLOID LOAD: A NOVEL BIOMARKER WITH INCREASED SENSITIVITY FOR β -AMYLOID. Alzheimer's and Dementia, 2017, 13, P1551.	0.8	0
68	PET Tau and Amyloid- β Burden in Mild Alzheimerâ€™s Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers. Journal of Alzheimer's Disease, 2017, 60, 283-293.	2.6	67
69	Comparison of four ¹¹ C-labeled PET ligands to quantify translocator protein 18kDa (TSPO) in human brain: (R)-PK11195, PBR28, DPA-713, and ER176â€‰based on recent publications that measured specific-to-non-displaceable ratios. EJNMMI Research, 2017, 7, 84.	2.5	80
70	Loss of extra-striatal phosphodiesterase 10A expression in early premanifest Huntington's disease gene carriers. Journal of the Neurological Sciences, 2016, 368, 243-248.	0.6	37
71	Glucagon increases energy expenditure independently of brown adipose tissue activation in humans. Diabetes, Obesity and Metabolism, 2016, 18, 72-81.	4.4	118
72	Evidence of Brain Inflammation in Patients with Human T-Lymphotropic Virus Type 1â€‰Associated Myelopathy (HAM): A Pilot, Multimodal Imaging Study Using ¹¹ C-PBR28 PET, MR T1-Weighted, and Diffusion-Weighted Imaging. Journal of Nuclear Medicine, 2016, 57, 1905-1912.	5.0	18

#	ARTICLE	IF	CITATIONS
73	Pseudo-healthy Image Synthesis for White Matter Lesion Segmentation. Lecture Notes in Computer Science, 2016, , 87-96.	1.3	19
74	Kinetic analysis of the translocator protein positron emission tomography ligand [18F]GE-180 in the human brain. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2201-2210.	6.4	70
75	Role of 18F-fluorodeoxyglucose Positron Emission Tomography in the Monitoring of Inflammatory Activity in Crohn's Disease. Inflammatory Bowel Diseases, 2016, 22, 2619-2629.	1.9	12
76	Blunted Endogenous Opioid Release Following an Oral Amphetamine Challenge in Pathological Gamblers. Neuropsychopharmacology, 2016, 41, 1742-1750.	5.4	96
77	Hippocampal Neuroinflammation, Functional Connectivity, and Depressive Symptoms in Multiple Sclerosis. Biological Psychiatry, 2016, 80, 62-72.	1.3	103
78	Phosphodiesterase 10A in Schizophrenia: A PET Study Using [¹¹ C]JMA107. American Journal of Psychiatry, 2016, 173, 714-721.	7.2	33
79	Neuroinflammation in treated HIV-positive individuals. Neurology, 2016, 86, 1425-1432.	1.1	136
80	Human Kinetic Modeling of the 5HT6 PET Radioligand [¹¹ C]-GSK215083 and Its Utility for Determining Occupancy at Both 5HT6 and 5HT2A Receptors by SB742457 as a Potential Therapeutic Mechanism of Action in Alzheimer Disease. Journal of Nuclear Medicine, 2015, 56, 1901-1909.	5.0	24
81	Simultaneous multiple kinect v2 for extended field of view motion tracking. , 2015, , .		2
82	The impact of the rs6971 polymorphism in TSPO for quantification and study design. Clinical and Translational Imaging, 2015, 3, 417-422.	2.1	28
83	Further evaluation of [11C]MP-10 as a radiotracer for phosphodiesterase 10A: PET imaging study in rhesus monkeys and brain tissue metabolite analysis. Synapse, 2015, 69, 86-95.	1.2	18
84	Altered PDE10A expression detectable early before symptomatic onset in Huntington's disease. Brain, 2015, 138, 3016-3029.	7.6	90
85	Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson's disease. Brain, 2015, 138, 3003-3015.	7.6	100
86	The Simplified Reference Tissue Model: Model Assumption Violations and Their Impact on Binding Potential. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 304-311.	4.3	77
87	Quantitative imaging of protein targets in the human brain with PET. Physics in Medicine and Biology, 2015, 60, R363-R411.	3.0	61
88	Impact of image-based motion correction on dopamine D3/D2 receptor occupancy: comparison of groupwise and frame-by-frame registration approaches. EJNMMI Physics, 2015, 2, 15.	2.7	11
89	An evaluation of the brain distribution of [11C]GSK1034702, a muscarinic-1 (M1) positive allosteric modulator in the living human brain using positron emission tomography. EJNMMI Research, 2014, 4, 66.	2.5	23
90	Determination of [¹¹ C]PBR28 Binding Potential <i>in vivo</i> : A First Human TSPO Blocking Study. Journal of Cerebral Blood Flow and Metabolism, 2014, 34, 989-994.	4.3	117

#	ARTICLE	IF	CITATIONS
91	Effect of chronic antipsychotic treatment on striatal phosphodiesterase 10A levels: a [¹¹ C]MP-10 PET rodent imaging study with ex vivo confirmation. <i>Translational Psychiatry</i> , 2014, 4, e376-e376.	4.8	16
92	In Vivo Imaging of Cerebral Dopamine D3 Receptors in Alcoholism. <i>Neuropsychopharmacology</i> , 2014, 39, 1703-1712.	5.4	53
93	A Graphical Method to Compare the <i>in vivo</i> Binding Potential of PET Radioligands in the Absence of a Reference Region: Application to [¹¹ C]PBR28 and [¹⁸ F]PBR111 for TSPO Imaging. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2014, 34, 1162-1168.	4.3	38
94	Amphetamine induced endogenous opioid release in the human brain detected with [¹¹ C]carfentanil PET: replication in an independent cohort. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 2069-2074.	2.1	85
95	Characterising the plasma-target occupancy relationship of the neurokinin antagonist GSK1144814 with PET. <i>Journal of Psychopharmacology</i> , 2014, 28, 244-253.	4.0	19
96	Connectivity-Based Functional Analysis of Dopamine Release in the Striatum Using Diffusion-Weighted MRI and Positron Emission Tomography. <i>Cerebral Cortex</i> , 2014, 24, 1165-1177.	2.9	276
97	Unexpectedly high affinity of a novel histamine H ₃ receptor antagonist, GSK239512, <i>in vivo</i> in human brain, determined using PET. <i>British Journal of Pharmacology</i> , 2014, 171, 1241-1249.	5.4	32
98	In Vivo Assessment of Brain White Matter Inflammation in Multiple Sclerosis with [¹⁸ F]-PBR111 PET. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1112-1118.	5.0	82
99	Phosphodiesterase 10A PET Radioligand Development Program: From Pig to Human. <i>Journal of Nuclear Medicine</i> , 2014, 55, 595-601.	5.0	50
100	Making drug development visible and viable. <i>Drug Discovery Today</i> , 2014, 19, 1-3.	6.4	12
101	Relationship Between Glycine Transporter 1 Inhibition as Measured with Positron Emission Tomography and Changes in Cognitive Performances in Nonhuman Primates. <i>Neuropsychopharmacology</i> , 2014, 39, 2742-2749.	5.4	22
102	Spatio-temporal pharmacokinetic model based registration of 4D PET neuroimaging data. <i>NeuroImage</i> , 2014, 84, 225-235.	4.2	12
103	PET neuroimaging: The elephant unpacks his trunk. <i>NeuroImage</i> , 2014, 94, 408-410.	4.2	3
104	Imaging Type 1 Glycine Transporters in the CNS Using Positron Emission Tomography. , 2014, , 321-330.		2
105	Imaging the Dopamine D3 Receptor In Vivo. , 2014, , 265-287.		3
106	Quantification of the Specific Translocator Protein Signal of [¹⁸ F]-PBR111 in Healthy Humans: A Genetic Polymorphism Effect on In Vivo Binding. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1915-1923.	5.0	105
107	Mathematical modelling of [¹¹ C]-(+)-PHNO human competition studies. <i>NeuroImage</i> , 2013, 68, 119-132.	4.2	33
108	Non linear mixed effects analysis in PET PK-receptor occupancy studies. <i>NeuroImage</i> , 2013, 76, 155-166.	4.2	4

#	ARTICLE	IF	CITATIONS
109	Kinetic Analysis of Drug-Target Interactions with PET for Characterization of Pharmacological Hysteresis. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 700-707.	4.3	13
110	A non-linear mixed effect modelling approach for metabolite correction of the arterial input function in PET studies. <i>NeuroImage</i> , 2013, 66, 611-622.	4.2	7
111	Monoamine Transporter Occupancy of a Novel Triple Reuptake Inhibitor in Baboons and Humans Using Positron Emission Tomography. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 346, 311-317.	2.5	16
112	A Generalised Spatio-Temporal Registration Framework for Dynamic PET Data: Application to Neuroreceptor Imaging. <i>Lecture Notes in Computer Science</i> , 2013, 16, 211-218.	1.3	3
113	Radiosynthesis and Characterization of ¹¹ C-GSK215083 as a PET Radioligand for the 5-HT ₆ Receptor. <i>Journal of Nuclear Medicine</i> , 2012, 53, 295-303.	5.0	53
114	Within-Subject Comparison of [¹¹ C]-(+)-PHNO and [¹¹ C]raclopride Sensitivity to Acute Amphetamine Challenge in Healthy Humans. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012, 32, 127-136.	4.3	150
115	An 18-kDa Translocator Protein (TSPO) Polymorphism Explains Differences in Binding Affinity of the PET Radioligand PBR28. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012, 32, 1-5.	4.3	642
116	Orbitofrontal Connectivity with Resting-State Networks Is Associated with Midbrain Dopamine D ₃ Receptor Availability. <i>Cerebral Cortex</i> , 2012, 22, 2784-2793.	2.9	62
117	Joint estimation of subject motion and tracer kinetic parameters of dynamic PET data in an EM framework. , 2012, , .		3
118	Combining PET Biodistribution and Equilibrium Dialysis Assays to Assess the Free Brain Concentration and BBB Transport of CNS Drugs. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012, 32, 874-883.	4.3	53
119	Endogenous Opioid Release in the Human Brain Reward System Induced by Acute Amphetamine Administration. <i>Biological Psychiatry</i> , 2012, 72, 371-377.	1.3	104
120	Identifying improved TSPO PET imaging probes through biomathematics: The impact of multiple TSPO binding sites in vivo. <i>NeuroImage</i> , 2012, 60, 902-910.	4.2	73
121	Affinity and selectivity of [¹¹ C]-(+)-PHNO for the D ₃ and D ₂ receptors in the rhesus monkey brain in vivo. <i>Synapse</i> , 2012, 66, 489-500.	1.2	74
122	Positron emission tomography molecular imaging for drug development. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 175-186.	2.4	263
123	A pharmacokinetic PET study of NK1 receptor occupancy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 226-235.	6.4	28
124	Spatial-temporal Pharmacokinetic Model Based Registration of 4D Brain PET Data. <i>Lecture Notes in Computer Science</i> , 2012, , 100-112.	1.3	2
125	Advances in biomathematical modeling for PET neuroreceptor imaging. <i>Drug Discovery Today: Technologies</i> , 2011, 8, e45-e51.	4.0	7
126	Evaluation of Novel <i>N</i> -Methyl-2-phenylindol-3-ylglyoxylamides as a New Chemotype of 18 kDa Translocator Protein-Selective Ligand Suitable for the Development of Positron Emission Tomography Radioligands. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 366-373.	6.4	25

#	ARTICLE	IF	CITATIONS
127	Imaging dopamine receptors in humans with [11C]-(+)-PHNO: Dissection of D3 signal and anatomy. <i>NeuroImage</i> , 2011, 54, 264-277.	4.2	359
128	Non-invasive imaging in experimental medicine for drug development. <i>Current Opinion in Pharmacology</i> , 2011, 11, 501-507.	3.5	32
129	Radiosynthesis and in vivo evaluation of [11C]MP-10 as a positron emission tomography radioligand for phosphodiesterase 10A. <i>Nuclear Medicine and Biology</i> , 2011, 38, 875-884.	0.6	42
130	MR-DTI and PET multimodal imaging of dopamine release within subdivisions of basal ganglia. <i>Journal of Physics: Conference Series</i> , 2011, 317, 012005.	0.4	2
131	Prediction of Repeat-Dose Occupancy from Single-Dose Data: Characterisation of the Relationship between Plasma Pharmacokinetics and Brain Target Occupancy. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2011, 31, 944-952.	4.3	59
132	Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans. <i>Molecular Psychiatry</i> , 2011, 16, 826-835.	7.9	89
133	Biodistribution and Radiation Dosimetry of the Glycine Transporter-1 Ligand 11C-GSK931145 Determined from Primate and Human Whole-Body PET. <i>Molecular Imaging and Biology</i> , 2011, 13, 776-784.	2.6	13
134	Characterization of in vivo pharmacological properties and sensitivity to endogenous serotonin of [¹¹ C] P943: A positron emission tomography study in <i>Papio anubis</i> . <i>Synapse</i> , 2011, 65, 1119-1127.	1.2	28
135	Translational characterization of [¹¹ C]GSK931145, a PET ligand for the glycine transporter type 1. <i>Synapse</i> , 2011, 65, 1319-1332.	1.2	46
136	Molecular and functional neuroimaging of human opioid receptor pharmacology. <i>Molecular Psychiatry</i> , 2011, 16, 785-785.	7.9	10
137	In Vivo Binding of Antipsychotics to D3 and D2 Receptors: A PET Study in Baboons with [11C]-(+)-PHNO. <i>Neuropsychopharmacology</i> , 2011, 36, 887-895.	5.4	41
138	Mixed-Affinity Binding in Humans with 18-kDa Translocator Protein Ligands. <i>Journal of Nuclear Medicine</i> , 2011, 52, 24-32.	5.0	330
139	Real-time adaptive sequential design for optimal acquisition of arterial spin labeling MRI data. <i>Magnetic Resonance in Medicine</i> , 2010, 64, 203-210.	3.0	14
140	Identification and evaluation of [¹¹ C]GSK931145 as a novel ligand for imaging the type 1 glycine transporter with positron emission tomography. <i>Synapse</i> , 2010, 64, 542-549.	1.2	33
141	Adaptive-Optimal Design in PET Occupancy Studies. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 87, 563-571.	4.7	29
142	Measuring Drug Occupancy in the Absence of a Reference Region: The Lassen Plot Re-Visited. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2010, 30, 46-50.	4.3	231
143	Imaging Cortical Dopamine D1 Receptors Using [11C]NNC112 and Ketanserin Blockade of the 5-HT _{2A} Receptors. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2010, 30, 985-993.	4.3	27
144	Two Binding Sites for [³ H]PBR28 in Human Brain: Implications for TSPO PET Imaging of Neuroinflammation. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2010, 30, 1608-1618.	4.3	187

#	ARTICLE	IF	CITATIONS
145	Pittsburgh Compound B (11C-PIB) and Fluorodeoxyglucose (18 F-FDG) PET in Patients With Alzheimer Disease, Mild Cognitive Impairment, and Healthy Controls. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2010, 23, 185-198.	2.3	103
146	Evaluation of 11C-GSK189254 as a Novel Radioligand for the H3 Receptor in Humans Using PET. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1021-1029.	5.0	68
147	Imaging Dopamine D3 Receptors in the Human Brain with Positron Emission Tomography, [11C]PHNO, and a Selective D3 Receptor Antagonist. <i>Biological Psychiatry</i> , 2010, 68, 392-399.	1.3	140
148	Differentiation of the Mu-opioid ligand GSK1521498 from naltrexone using [11C]carfentanil PET and fMRI. <i>NeuroImage</i> , 2010, 52, S78.	4.2	0
149	PET evaluation of the TSPO ligands [F-18]FEPPA, [F-18]PRB06, and [F-18]PBR111 in nonhuman primate. <i>NeuroImage</i> , 2010, 52, S147.	4.2	0
150	Effect of cellular compartments on the binding of [3H](+)PhNO to the porcine D2/D3-DAR. <i>NeuroImage</i> , 2010, 52, S167.	4.2	0
151	Awake nonhuman primate brain PET imaging without head restraint. <i>NeuroImage</i> , 2010, 52, S18.	4.2	1
152	A combined diffusion tensor imaging (DTI) and [11C]-(+)-PHNO positron emission tomography (PET) study to quantify dopamine D3/D2 receptors in pallidum. <i>NeuroImage</i> , 2010, 52, S23.	4.2	0
153	PBR28, PBR06 and PBR111 bind two distinct TSPO sites in human brain tissue. <i>NeuroImage</i> , 2010, 52, S30-S31.	4.2	0
154	Evaluation of the in vivo ED50 for the PET Radioligand, [11C]GSK-215083, in <i>Papio anubis</i> . <i>NeuroImage</i> , 2010, 52, S37.	4.2	1
155	Impact of scatter correction on D2 receptor occupancy measurements using 123I-IBZM SPECT: Comparison to 11C-Raclopride PET. <i>NeuroImage</i> , 2010, 50, 1511-1518.	4.2	12
156	11C-GSK189254: A Selective Radioligand for In Vivo Central Nervous System Imaging of Histamine H3 Receptors by PET. <i>Journal of Nuclear Medicine</i> , 2009, 50, 2064-2072.	5.0	42
157	Kinetic Modeling of ¹¹ C-SB207145 Binding to 5-HT ₄ Receptors in the Human Brain In Vivo. <i>Journal of Nuclear Medicine</i> , 2009, 50, 900-908.	5.0	84
158	A Biomathematical Modeling Approach to Central Nervous System Radioligand Discovery and Development. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1715-1723.	5.0	68
159	Positron emission tomography imaging of amphetamine-induced dopamine release in the human cortex: A comparative evaluation of the high affinity dopamine D _{2/3} radiotracers [¹¹ C]FLB 457 and [¹¹ C]fallypride. <i>Synapse</i> , 2009, 63, 447-461.	1.2	127
160	In vivo quantification of regional dopamine D3 receptor binding potential of (+)-PHNO: Studies in nonhuman primates and transgenic mice. <i>Synapse</i> , 2009, 63, 782-793.	1.2	127
161	Dopamine D3 receptor antagonists: The quest for a potentially selective PET ligand. Part 3: Radiosynthesis and in vivo studies. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 5056-5059.	2.2	24
162	Within-subject comparison of striatal D2 receptor occupancy measurements using [123I]IBZM SPECT and [11C]Raclopride PET. <i>NeuroImage</i> , 2009, 46, 447-458.	4.2	33

#	ARTICLE	IF	CITATIONS
163	Optimal design of pulsed arterial spin labeling MRI experiments. <i>Magnetic Resonance in Medicine</i> , 2008, 59, 826-834.	3.0	41
164	Dynamic Positron Emission Tomography Data-Driven Analysis Using Sparse Bayesian Learning. <i>IEEE Transactions on Medical Imaging</i> , 2008, 27, 1356-1369.	8.9	24
165	[11C](+)RX-821024: A novel tracer for imaging $\hat{1}\pm 2$ -adrenoceptors. <i>NeuroImage</i> , 2008, 41, T98.	4.2	0
166	Gender and cognitive performance: Correlations to 5-HT ₄ receptors in the human brain: A 11C-SB207145-PET study. <i>NeuroImage</i> , 2008, 41, T160.	4.2	0
167	Kinetic analysis of [11C]GSK189254, a novel radioligand for the H ₃ receptor in humans using positron emission tomography (PET). <i>NeuroImage</i> , 2008, 41, T14.	4.2	2
168	Evaluation of the novel 5-HT ₆ receptor radioligand, [11C]GSK-215083 in human. <i>NeuroImage</i> , 2008, 41, T20.	4.2	13
169	[11C]GSK931145: A new pet ligand for glycine transporter 1. <i>NeuroImage</i> , 2008, 41, T21.	4.2	6
170	Voxel-Based Analysis of ¹¹ C-PIB Scans for Diagnosing Alzheimer's Disease. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1262-1269.	5.0	41
171	Toward an improved prediction of human <i>in vivo</i> brain penetration. <i>Xenobiotica</i> , 2008, 38, 1518-1535.	1.1	105
172	Consensus Nomenclature for <i>in vivo</i> Imaging of Reversibly Binding Radioligands. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2007, 27, 1533-1539.	4.3	1,840
173	Bayesian kinetic modelling. <i>NeuroImage</i> , 2006, 31, T71.	4.2	0
174	Modeling Sensitization to Stimulants in Humans. <i>Archives of General Psychiatry</i> , 2006, 63, 1386-95.	12.3	255
175	POSITRON EMISSION TOMOGRAPHY - TRACER KINETIC MODELLING IN DRUG DEVELOPMENT. , 2006, , .		0
176	Estimation of serotonin transporter parameters with 11C-DASB in healthy humans: reproducibility and comparison of methods. <i>Journal of Nuclear Medicine</i> , 2006, 47, 815-26.	5.0	69
177	Statistical estimation with Kronecker products in positron emission tomography. <i>Linear Algebra and Its Applications</i> , 2005, 398, 25-36.	0.9	4
178	Statistical Maps for EEG Dipolar Source Localization. <i>IEEE Transactions on Biomedical Engineering</i> , 2005, 52, 401-413.	4.2	27
179	Behaviour of [11C]R(?) - and [11C]S(+)-rolipram <i>in vitro</i> and <i>in vivo</i> , and their use as PET radiotracers for the quantitative assay of PDE4. <i>Synapse</i> , 2005, 55, 270-279.	1.2	30
180	2-[11C]Thymidine Positron Emission Tomography Reproducibility in Humans. <i>Clinical Cancer Research</i> , 2005, 11, 4341-4347.	7.0	19

#	ARTICLE	IF	CITATIONS
181	Wavelet variance components in image space for spatiotemporal neuroimaging data. <i>NeuroImage</i> , 2005, 25, 159-168.	4.2	18
182	PET studies in drug development: Methodological considerations. <i>Drug Discovery Today: Technologies</i> , 2005, 2, 311-315.	4.0	34
183	Investigation of acute modulation of cAMP in vivo with PET using [11C]rolipram. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, S663-S663.	4.3	0
184	Preferential 5-HT1A Autoreceptor Occupancy by Pindolol is Attenuated in Depressed Patients: Effect of Treatment or an Endophenotype of Depression?. <i>Neuropsychopharmacology</i> , 2004, 29, 1688-1698.	5.4	33
185	Decreasing Amphetamine-Induced Dopamine Release by Acute Phenylalanine/Tyrosine Depletion: A PET/[11C]Raclopride Study in Healthy Men. <i>Neuropsychopharmacology</i> , 2004, 29, 427-432.	5.4	87
186	Dopamine Transmission in the Human Striatum during Monetary Reward Tasks. <i>Journal of Neuroscience</i> , 2004, 24, 4105-4112.	3.6	210
187	PET quantification of muscarinic cholinergic receptors with [N-11C-methyl]-bentropine and application to studies of propofol-induced unconsciousness in healthy human volunteers. <i>Synapse</i> , 2004, 51, 91-101.	1.2	21
188	Parametrically defined cerebral blood vessels as non-invasive blood input functions for brain PET studies. <i>Physics in Medicine and Biology</i> , 2004, 49, 1033-1054.	3.0	21
189	A bolus/infusion paradigm for the novel NMDA receptor SPET tracer [123I]CNS 1261. <i>Nuclear Medicine and Biology</i> , 2004, 31, 155-164.	0.6	30
190	Kinetic analysis of neuroreceptor binding using PET. <i>International Congress Series</i> , 2004, 1265, 12-24.	0.2	7
191	PET-SORTEO: A Monte Carlo-Based Simulator With High Count Rate Capabilities. <i>IEEE Transactions on Nuclear Science</i> , 2004, 51, 46-52.	2.0	89
192	Bootstrapped DEPICT for error estimation in PET functional imaging. <i>NeuroImage</i> , 2004, 21, 1096-1104.	4.2	14
193	Quantification in positron emission tomography for research in pharmacology and drug development. <i>Nuclear Medicine Communications</i> , 2004, 25, 643-646.	1.1	32
194	Evaluation of NMDA Receptors in Vivo in Schizophrenic Patients with [123I]CNS 1261 and SPET. <i>Annals of the New York Academy of Sciences</i> , 2003, 1003, 364-367.	3.8	13
195	Kinetic modelling of [123I]CNS 1261—a potential SPET tracer for the NMDA receptor. <i>Nuclear Medicine and Biology</i> , 2003, 30, 441-454.	0.6	46
196	2-[11C]Thymidine Positron Emission Tomography as an Indicator of Thymidylate Synthase Inhibition in Patients Treated With AG337. <i>Journal of the National Cancer Institute</i> , 2003, 95, 675-682.	6.3	67
197	Rank-shaping regularization of exponential spectral analysis for application to functional parametric mapping. <i>Physics in Medicine and Biology</i> , 2003, 48, 3819-3841.	3.0	36
198	Wavelet variance components in image space for spatio-temporal neuroimaging data. , 2003, , .		0

#	ARTICLE	IF	CITATIONS
199	Evaluation of EMD 128 130 occupancy of the 5-HT1A and the D2 receptor: a human PET study with [11]WAY-100635 and [11C]raclopride. Journal of Psychopharmacology, 2002, 16, 195-199.	4.0	40
200	5-Hydroxytryptamine 1A Receptor Occupancy by Novel Full Antagonist 2-[4-[4-(7-Chloro-2,3-dihydro-1,4-benzodioxyn-5-yl)-1-piperazinyl]butyl]-1,2-benzisothiazol-3-(2H)-one,1,1-dioxide: A [11C][O-methyl-3H]-N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide Trihydrochloride (WAY-100635) Positron Emission Tomography Study in Humans. Journal of Pharmacology and Experimental Therapeutics, 2002, 301, 1144-1150.	2.5	44
201	A Database of [11C]WAY-100635 Binding to 5-HT1A Receptors in Normal Male Volunteers: Normative Data and Relationship to Methodological, Demographic, Physiological, and Behavioral Variables. NeuroImage, 2002, 15, 620-632.	4.2	133
202	Positron Emission Tomography Partial Volume Correction: Estimation and Algorithms. Journal of Cerebral Blood Flow and Metabolism, 2002, 22, 1019-1034.	4.3	161
203	Positron Emission Tomography Compartmental Models: A Basis Pursuit Strategy for Kinetic Modeling. Journal of Cerebral Blood Flow and Metabolism, 2002, 22, 1425-1439.	4.3	181
204	Tracer Kinetic Modeling via Basis Pursuit. , 2002, , 115-121.		4
205	Positron Emission Tomography Compartmental Models: A Basis Pursuit Strategy for Kinetic Modeling. Journal of Cerebral Blood Flow and Metabolism, 2002, , 1425-1439.	4.3	79
206	The PET radioligand [carbonyl-(11)C]desmethyl-WAY-100635 binds to 5-HT(1A) receptors and provides a higher radioactive signal than [carbonyl-(11)C]WAY-100635 in the human brain. Journal of Nuclear Medicine, 2002, 43, 292-303.	5.0	32
207	Assessment of proliferation in vivo using 2-[(11)C]thymidine positron emission tomography in advanced intra-abdominal malignancies. Cancer Research, 2002, 62, 5698-702.	0.9	60
208	PET measurement of the influence of corticosteroids on serotonin-1A receptor number. Biological Psychiatry, 2001, 50, 668-676.	1.3	25
209	In-vivo measurement of activated microglia in dementia. Lancet, The, 2001, 358, 461-467.	13.7	983
210	Long-term trans-synaptic glial responses in the human thalamus after peripheral nerve injury. NeuroReport, 2001, 12, 3439-3442.	1.2	108
211	Pindolol Augmentation of Selective Serotonin Reuptake Inhibitors: PET Evidence That the Dose Used in Clinical Trials Is Too Low. American Journal of Psychiatry, 2001, 158, 2080-2082.	7.2	80
212	Analyses of [18F]altanserin bolus injection PET data. II: Consideration of radiolabeled metabolites in humans. Synapse, 2001, 41, 11-21.	1.2	54
213	Reduced dopamine D1 receptor binding in the ventral striatum of cigarette smokers. Synapse, 2001, 42, 48-53.	1.2	118
214	Positron Emission Tomography Compartmental Models. Journal of Cerebral Blood Flow and Metabolism, 2001, 21, 635-652.	4.3	470
215	In vivo visualization of activated glia by [11C] (R)-PK11195-PET following herpes encephalitis reveals projected neuronal damage beyond the primary focal lesion. Brain, 2001, 124, 2014-2027.	7.6	153
216	Markov Random Field Models for Segmentation of PET Images. Lecture Notes in Computer Science, 2001, , 468-474.	1.3	36

#	ARTICLE	IF	CITATIONS
217	Small Animal PET Enables Parametric Mapping of Saturation Kinetics at the 5-HT1A Receptor. , 2001, , 171-176.		2
218	Analysis of Functional Imaging Data Sets via Functional Segmentation. , 2001, , 45-50.		0
219	Imaging Activated Microglia in the Aging Human Brain. , 2001, , 361-367.		4
220	Pindolol occupancy of 5-HT1A receptors measured in vivo using small animal positron emission tomography with carbon-11 labeled WAY 100635. , 2000, 36, 330-341.		43
221	Modeling Dynamic PET-SPECT Studies in the Wavelet Domain. Journal of Cerebral Blood Flow and Metabolism, 2000, 20, 879-893.	4.3	54
222	β-blocker Binding to Human 5-HT1A Receptors in vivo and in vitro Implications for Antidepressant Therapy. Neuropsychopharmacology, 2000, 23, 285-293.	5.4	70
223	Evaluation of [O-methyl - 11 C]RS-15385-197 as a positron emission tomography radioligand for central β± 2 -adrenoceptors. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 475-484.	6.4	20
224	Brain Serotonin1A Receptor Binding Measured by Positron Emission Tomography With [11C]WAY-100635. Archives of General Psychiatry, 2000, 57, 174.	12.3	597
225	Quantitative analysis of [carbonyl-11C]WAY-100635 PET studies. Nuclear Medicine and Biology, 2000, 27, 477-482.	0.6	46
226	Drug action at the 5-HT1A receptor in vivo: autoreceptor and postsynaptic receptor occupancy examined with PET and [carbonyl-11C]WAY-100635. Nuclear Medicine and Biology, 2000, 27, 509-513.	0.6	63
227	A Statistical Method for the Analysis of Positron Emission Tomography Neuroreceptor Ligand Data. NeuroImage, 2000, 12, 245-256.	4.2	78
228	S54.02 Using pet to study dopamine release in vivo. European Psychiatry, 2000, 15, 317s-318s.	0.2	0
229	Steps to a neurochemistry of personality. Behavioral and Brain Sciences, 1999, 22, 528-529.	0.7	2
230	Huntington's disease progression. Brain, 1999, 122, 2353-2363.	7.6	193
231	Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nature Neuroscience, 1999, 2, 1137-1140.	14.8	663
232	Assessment of Spatial Normalization of PET Ligand Images Using Ligand-Specific Templates. NeuroImage, 1999, 9, 545-553.	4.2	165
233	Evidence for striatal dopamine release during a video game. Nature, 1998, 393, 266-268.	27.8	1,079
234	Pharmacological constraints associated with positron emission tomographic scanning of small laboratory animals. European Journal of Nuclear Medicine and Molecular Imaging, 1998, 25, 173-176.	6.4	198

#	ARTICLE	IF	CITATIONS
235	Characterisation of the Appearance of Radioactive Metabolites in Monkey and Human Plasma from the 5-HT1A Receptor Radioligand, [carbonyl-11C]WAY-100635"Explanation of High Signal Contrast in PET and an Aid to Biomathematical Modelling. Nuclear Medicine and Biology, 1998, 25, 215-223.	0.6	91
236	A procedure for generating locally identifiable reparameterisations of unidentifiable non-linear systems by the similarity transformation approach. Mathematical Biosciences, 1998, 148, 21-41.	1.9	42
237	Tracer Kinetic Modeling of the 5-HT1A Receptor Ligand [carbonyl-11C]WAY-100635 for PET. NeuroImage, 1998, 8, 426-440.	4.2	267
238	[11C]raclopride pet detects dopamine release induced by behavioural manipulation. Schizophrenia Research, 1998, 29, 94.	2.0	1
239	Measuring Neurotransmitter Release with PET: Methodological Issues 1 1Transcripts of the BRAINPET97 discussion of this chapter can be found in Section VIII.. , 1998, , 449-454.		24
240	Suppression of Noise Artifacts in Spectral Analysis of Dynamic PET Data 1 1Transcripts of the BRAINPET97 discussion of this chapter can be found in Section VIII.. , 1998, , 329-334.		4
241	Parametric Imaging of Ligand-Receptor Interactions Using a Reference Tissue Model and Cluster Analysis. , 1998, , 401-406.		17
242	Demonstration of clomipramine and venlafaxine occupation at serotonin reuptake sites in man in vivo. Journal of Psychopharmacology, 1997, 11, 279-281.	4.0	9
243	Reparameterisation of Unidentifiable Systems using the Taylor Series Approach. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 1997, 30, 247-252.	0.4	2
244	Parametric Imaging of Ligand-Receptor Binding in PET Using a Simplified Reference Region Model. NeuroImage, 1997, 6, 279-287.	4.2	998
245	Benzodiazepine Site Pharmacokinetic/Pharmacodynamic Quantification in Man: Direct Measurement of Drug Occupancy and Effects on the Human Brain In Vivo. Neuropharmacology, 1996, 35, 1483-1491.	4.1	45
246	Non-invasive measurement of left ventricular volumes and function by gated positron emission tomography. European Journal of Nuclear Medicine and Molecular Imaging, 1996, 23, 1594-1602.	2.1	29
247	A new human (psycho)pharmacology tool: the multiple organs coincidences counter (MOCC). Journal of Psychopharmacology, 1995, 9, 294-306.	4.0	14